Minerva Neurosciences Depreciation & Amortization Growth & History (NERV)
Minerva Neurosciences's depreciation and amortization was $5,442 for fiscal 2025.
View full Minerva Neurosciences company overviewMinerva Neurosciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5,442 | $0 | 0.00% |
| 2024 | 2024-12-31 | $5,442 | $0 | 0.00% |
| 2023 | 2023-12-31 | $5,442 | −$3,071 | −36.07% |
| 2022 | 2022-12-31 | $8,513 | — | — |
| 2020 | 2020-12-31 | $16,011 | −$1,456 | −8.34% |
| 2019 | 2019-12-31 | $17,467 | $0 | 0.00% |
| 2018 | 2018-12-31 | $17,467 | $6,373 | +57.45% |
| 2017 | 2017-12-31 | $11,094 | −$5,436 | −32.89% |
| 2016 | 2016-12-31 | $16,530 | −$746 | −4.32% |
| 2015 | 2015-12-31 | $17,276 | −$16,593 | −48.99% |
| 2014 | 2014-12-31 | $33,869 | — | — |
Minerva Neurosciences quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$1,360 | — |
| Q1 2026 | 2026-03-31 | $0 | −$1,361 | — |
| Q4 2025 | 2025-12-31 | $1,360 | — | — |
| Q3 2025 | 2025-09-30 | $1,361 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $1,360 | −$1 | −0.07% |
| Q1 2025 | 2025-03-31 | $1,361 | $1 | +0.07% |
| Q3 2024 | 2024-09-30 | $1,361 | $1 | +0.07% |
| Q2 2024 | 2024-06-30 | $1,361 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $1,360 | $0 | 0.00% |
| Q3 2023 | 2023-09-30 | $1,360 | — | — |
| Q2 2023 | 2023-06-30 | $1,361 | — | — |
| Q1 2023 | 2023-03-31 | $1,360 | — | — |
| Q3 2020 | 2020-09-30 | $4,367 | $1 | +0.02% |
| Q2 2020 | 2020-06-30 | $4,366 | −$1 | −0.02% |
| Q1 2020 | 2020-03-31 | $4,367 | $0 | 0.00% |
| Q3 2019 | 2019-09-30 | $4,366 | $0 | 0.00% |
| Q2 2019 | 2019-06-30 | $4,367 | $0 | 0.00% |
| Q1 2019 | 2019-03-31 | $4,367 | $0 | 0.00% |
| Q3 2018 | 2018-09-30 | $4,366 | $1,660 | +61.35% |
| Q2 2018 | 2018-06-30 | $4,367 | $1,065 | +32.25% |
| Q1 2018 | 2018-03-31 | $4,367 | $1,065 | +32.25% |
| Q3 2017 | 2017-09-30 | $2,706 | −$1,614 | −37.36% |
| Q2 2017 | 2017-06-30 | $3,302 | −$1,017 | −23.55% |
| Q1 2017 | 2017-03-31 | $3,302 | −$1,018 | −23.56% |
| Q3 2016 | 2016-09-30 | $4,320 | $0 | 0.00% |
| Q2 2016 | 2016-06-30 | $4,319 | — | — |
| Q1 2016 | 2016-03-31 | $4,320 | −$5,391 | −55.51% |
| Q3 2015 | 2015-09-30 | $4,320 | −$21,288 | −83.13% |
| Q1 2015 | 2015-03-31 | $9,711 | $9,441 | +3496.67% |
| Q3 2014 | 2014-09-30 | $25,608 | — | — |
| Q2 2014 | 2014-06-30 | $4,001 | — | — |
| Q1 2014 | 2014-03-31 | $270 | — | — |
Minerva Neurosciences depreciation and amortization trends
Over the last five fiscal years, Minerva Neurosciences's depreciation and amortization decreased from $16,011 to $5,442, a change of −$10,569. The latest reported quarter, Q2 2026, shows $0.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Minerva Neurosciences source filings ↗